PMN

ProMIS Neurosciences, Inc.'s stock price decreased by 22.05% from May 7, 2025, to May 6, 2026, with a 52-week trading range between $6.27 and $39.75. Key events include completing enrollment for the PRECISE-AD Phase 1b clinical trial in December 2025, announcing a private placement financing of up to $175 million in January 2026, closing a private placement for $75.5 million in February 2026, announcing Full Year 2025 Financial Results in March 2026, presenting data on ALS and Parkinson's Disease programs at the AD/PD™ conference in March 2026, participating in the Bloom Burton & Co. Healthcare Investor Conference in April 2026, and scheduling its 2026 Annual Meeting of Stockholders in May 2026. Upcoming catalysts include the expected blinded 6-month top-line data from the PRECISE-AD study in mid-2026, a blinded interim analysis anticipated in early Q3 2026, and 12-month top-line data expected in early 2027.